Immunome, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage biotechnology company developing targeted cancer therapeutics through its proprietary human memory B cell platform, which identifies novel antibodies and antigen targets for oncology applications. The company leverages this platform to discover and develop product candidates including AL102, a gamma secretase inhibitor for desmoid tumors licensed from Ayala Pharmaceuticals; QUILT-series combination immunotherapies incorporating checkpoint inhibitors, cytokines, and proprietary vaccines; and next-generation bispecific antibodies such as IMM01 targeting KLK3 and CD3 for prostate cancer and IMM02 targeting CLEVER-1 and CD3 for solid tumors. Its pipeline also encompasses MEM-01, a macropinocytosis inhibitor, and additional assets like MEM-02 and MEM-100, focusing on precision oncology for difficult-to-treat cancers; services include antibody discovery and validation for internal and partnered programs. Founded in 2006 and headquartered in Exton, Pennsylvania, Immunome operates primarily in the United States with a global focus on pharmaceutical partnerships and clinical trials across North America and Europe, targeting oncologists, cancer centers, and biopharma collaborators. Recent developments include the September 2024 acquisition of MorphImmune for $139 million, expanding its bispecific T cell engager portfolio with preclinical assets advancing toward IND filings; a December 2024 strategic collaboration with the Parker Institute for Cancer Immunotherapy to co-develop QUILT-3.072 in non-small cell lung cancer; positive interim Phase 1 data for IMM01 presented at SITC 2024 showing favorable safety and pharmacokinetics; and ongoing enrollment in the MEM-01 monotherapy and MEM-01/KEYTRUDA combination trials for pancreatic cancer, alongside preparations for a registrational trial in desmoid tumors pending FDA feedback.
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome: Upcoming NDA, Valuation, And Investment Case
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Immunome to Present at Upcoming Investor Conferences
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More